Hemay808

Tianjin Hemay Pharmaceutical Co., Ltd · Phase 2 active Small molecule

At a glance

Generic name	Hemay808
Sponsor	Tianjin Hemay Pharmaceutical Co., Ltd
Modality	Small molecule
Phase	Phase 2

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

A Phase Ⅱ Study of Hemay808 for Atopic Dermatitis Patients (PHASE2)
A Phase I Clinical Study of Hemay808 (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Hemay808 CI brief — competitive landscape report
Hemay808 updates RSS · CI watch RSS
Tianjin Hemay Pharmaceutical Co., Ltd portfolio CI